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Introduction {#sec1}
============

During neural development, the generation of the appropriate type and number of differentiated neurons and glial cells is controlled by a complex interplay between extrinsic and intrinsic cues acting on neural progenitors, thus regulating the balance between differentiation and self-renewal ([@bib54], [@bib67], [@bib75]).

In the developing cortex, radial glial cells are the main progenitors that will differentiate into specific postmitotic neuron populations, directly or through various classes of intermediate progenitors ([@bib22], [@bib41]). Proneural factors act on these progenitors as the main intrinsic drivers of neurogenesis ([@bib23], [@bib24]), through cross-repression with the Notch pathway, which promotes self-renewal, and by directly inducing various classes of genes involved in neuronal differentiation. Key features of the Notch signaling pathway, such as lateral inhibition and oscillatory behavior, contribute in a major way to the irreversible commitment of differentiating cells toward neuronal fate ([@bib33]). Moreover, many classes of extrinsic morphogen cues, including Wnt ligands, Sonic Hedgehog (SHH), and fibroblast growth factors (FGFs) can act on cortical progenitors to promote expansion and self-renewal and thereby effectively block neurogenesis ([@bib8], [@bib35], [@bib48], [@bib65], [@bib79]).

Intriguingly, it has long been proposed that postmitotic cells undergoing neuronal differentiation become insulated from extrinsic signaling ([@bib14]). Whether and how responsiveness to extrinsic cues is negatively modulated to allow neuronal commitment remains essentially unclear. Delamination of the progenitors away from the ventricular zone could contribute to this process, as some of these cues are secreted in the embryonic cerebrospinal fluid and are thought to act through the apical processes or cilia of the radial glial cells ([@bib47]). However, several cues, most strikingly Wnts, are also present in the cortical tissue ([@bib25]), where they can act on progenitors to block differentiation.

Moreover, the signaling components of these various pathways, as well as some key downstream targets, are often partially overlapping. For instance, cross-talk of the Notch and Wnt pathways ([@bib26]), or Notch and FGFs ([@bib65]), has been documented during embryonic development and, despite the relatively simple intracellular regulation of the Wnt/β-catenin pathway, many of its components are used by other pathways or participate in distinct cellular activities. For instance, the deletion of *Gsk3a/b*, a major intracellular component of the β-catenin destruction complex, increases the proliferation of radial glial cells at the expense of their differentiation by altering not only Wnt but also Notch and FGF signaling activity ([@bib40]). Also, some key effectors genes, such as *Cyclin d1/d2*, are found as common targets of all morphogen pathways, depending on cellular context ([@bib11], [@bib34], [@bib37], [@bib61], [@bib71]). How these intermingled pathways are effectively shut down during neurogenesis is therefore a complex issue and remains largely unresolved.

We previously reported that the transcriptional repressor Bcl6 ([@bib4], [@bib7]) is required for neuronal differentiation in the cerebral cortex and directly represses the Notch-dependent *Hes5* target ([@bib74]), and in the cerebellum, Bcl6 promotes neurogenesis through repression of SHH pathway effectors *Gli1/2* ([@bib76]). This raises the question whether Bcl6 promotes neurogenic conversion through the repression of distinct targets, depending on the cellular context, or through a more generic transcriptional repression program.

Here, we combine transcriptome, epigenome, and *in vivo* functional analyses to determine the molecular logic of action of Bcl6 during neurogenesis, focusing on the cerebral cortex. We find that Bcl6 acts as a global repressor of a repertoire of signaling components of most signaling pathways known to promote self-renewal, including Notch, SHH, FGF, and most strikingly the Wnt pathway. These data define a molecular logic of neurogenesis whereby a single intrinsic factor downregulates the responsiveness to extrinsic cues, through transcriptional repression at multiple parallel and serial levels along these pathways, to ensure irreversible neurogenic fate transition.

Results {#sec2}
=======

Bcl6 Upregulates an Intrinsic Neurogenic Program and Downregulates Extrinsic Proliferative Pathways {#sec2.1}
---------------------------------------------------------------------------------------------------

To determine the primary molecular mechanisms of Bcl6 action in cortical neurogenesis, we performed RNA sequencing (RNA-seq) transcriptome analysis on *in vitro* embryonic-stem-cell-derived cortical progenitors driving inducible Bcl6 expression in order to timely control the transgene induction ([Figure 1](#fig1){ref-type="fig"}A; [@bib18], [@bib74]). We found that, 24 h following Bcl6 induction, 764 genes were significantly upregulated, with *Bcl6* being the most increased, and 610 genes were significantly downregulated, with *Hes5* being the most repressed ([Table S1](#mmc2){ref-type="supplementary-material"}).Figure 1Bcl6 Promotes a Neurogenic Transcription Program and Represses Selective Genes of the Main Proliferative Pathways(A) Scheme representing the differentiation protocol of Bcl6-inducible A2 lox.Cre mouse embryonic stem cells into cortical progenitors. Bcl6 expression was induced at day 12 using a single doxycycline pulse for 24 h.(B) Gene Ontology analysis showing statistically significant enrichment for some categories of up- and downregulated genes following Bcl6 induction (see also [Table S2](#mmc3){ref-type="supplementary-material"} for complete lists).(C) Histograms representing the log-fold change of a series of significantly up- or downregulated genes, respectively indicated in red or blue, selected upon their expression and/or function during cortical differentiation. IP, intermediate progenitors; NE, neuroepithelial cells; RGC, radial glial cells (see also [Table S1](#mmc2){ref-type="supplementary-material"} for complete lists).(D) Histograms representing the log-fold change of significantly up- or downregulated genes, respectively indicated in red or blue, belonging to the main proliferative pathways in cortical progenitors. Only the potential target genes with known expression in embryonic cortical progenitors are indicated. For the complete list of genes taken into consideration for the analysis, see also [Table S3](#mmc4){ref-type="supplementary-material"}. Genes marked with an asterisk also are target genes of the pathway itself. SVZ, subventricular zone; VZ, ventricular zone.(E) Scheme of the canonical Wnt pathway depicting the role in the cascade of the ensemble of Wnt/β-catenin-related genes bound and/or altered by Bcl6 investigated in this study.(F) qRT-PCR analysis of the Notch target *Hes5*, Wnt-related genes *Ctnnb1* and *Ccnd2*, and the cell fate markers *Pax6*, *Eomes*, and *Tubb3* in day 12 *in vitro* cortical progenitor cells treated with DMSO (control) or doxycycline for 6, 12, or 24 h. Data are presented as mean + SEM of Dox over control (Ctrl) absolute levels (n = 7--9 \[6 h\], 27--30 \[12 h\], and 9 \[24 h\] from at least 3 independent differentiations for each group). ^∗^p \< 0.05; ^∗∗^p \< 0.01 using Student's t test. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Gene Ontology analysis of the upregulated genes revealed a significant enrichment in categories linked to development and cell or neuron differentiation ([Figure 1](#fig1){ref-type="fig"}B; [Table S2](#mmc3){ref-type="supplementary-material"}). More specifically, most of the canonical markers of differentiation into intermediate progenitors and neurons were significantly upregulated ([Figure 1](#fig1){ref-type="fig"}C; [Table S1](#mmc2){ref-type="supplementary-material"}). On the other hand, downregulated genes showed an enrichment in gene categories linked to regulation of translation, negative regulation of neurogenesis, and most strikingly to signaling pathways promoting the expansion and self-renewal of cortical progenitors ([Figure 1](#fig1){ref-type="fig"}B; [Table S2](#mmc3){ref-type="supplementary-material"}). Among the significantly downregulated genes, we found, as expected, markers of radial glial cells and transcriptional targets of Notch but also many signaling components of FGF and SHH-dependent pathways and, most strikingly, a high number of genes belonging to the Wnt signaling cascade, from ligands to receptors to target genes ([Figures 1](#fig1){ref-type="fig"}C--1E; [Tables S1](#mmc2){ref-type="supplementary-material"} and [S3](#mmc4){ref-type="supplementary-material"}). Given that Bcl6 has strong effects on neurogenesis, it could be that these global transcriptional changes reflect the consequence of changes in cell fate rather than direct regulation by Bcl6. However, the majority of the tested genes belonging to these proliferative pathways (8/11) were downregulated following Bcl6 induction several hours earlier than changes in cell fate markers ([Figures 1](#fig1){ref-type="fig"}F and [S1](#mmc1){ref-type="supplementary-material"}A), indicating that their downregulation is not the mere result of Bcl6-mediated differentiation.

*Bcl6* Functionally Alters β-Catenin/Tcf Signaling to Promote Neurogenesis {#sec2.2}
--------------------------------------------------------------------------

Given the importance of the Wnt pathway in the regulation of self-renewal versus differentiation balance in the cortex ([@bib8], [@bib15], [@bib27], [@bib28], [@bib42], [@bib58], [@bib59], [@bib81], [@bib88]) and the number of downregulated genes belonging to this pathway, we tested the global impact of Bcl6 on the Wnt pathway *in vivo*. *Axin 2*, a classical Wnt/β-catenin-dependent target gene, was found to be upregulated in *Bcl6*^*−/−*^ mouse embryonic cortex using *in situ* hybridization. Although *Axin2* expression is normally detected in the medial pallium of the frontal cortex in wild-type animals, a higher signal was found throughout dorsolateral levels in *Bcl6*^*−/−*^ mice ([Figures 2](#fig2){ref-type="fig"}A and 2B), suggesting that β-catenin/Tcf activity is increased in the mutant cortex. Interestingly, this difference was not detectable at more posterior levels ([Figures 2](#fig2){ref-type="fig"}A and 2B), in accordance with the frontal high occipital low graded *Bcl6* expression ([@bib74]). Given that these gene expression changes are specific to the frontal cortex, we tested whether they could affect areal patterning in the mutant mice. However, analysis of the pattern of expression of several area-specific markers did not detect any obvious changes in areal patterning in the *Bcl6* mutant mice ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2J), suggesting that Bcl6 effect on the Wnt pathways does not affect regional patterning of the cortex.Figure 2*Bcl6* Alters β-Catenin Signaling *In Vivo* to Promote Neurogenesis(A) *In situ* hybridization of *Axin2* Wnt reporter gene on coronal sections of E12.5 wild-type and *Bcl6*^−/−^ frontal and parietal telencephalon. Scale bars, 500 μm.(B) Normalized gray scale quantifications of *Axin2* levels were performed using ImageJ software. Data are presented as mean + SEM. ^∗^p \< 0.05 using Student's t test.(C--E) *In utero* electroporation of pCIG, pCIG+pCAG-Δ(1-90)*Ctnnb1*, pCIG-*Bcl6*+pCIG or pCIG-*Bcl6*+pCAG-Δ(1-90)*Ctnnb1* at E13.5.(C) Hoechst and GFP immunofluorescence was performed on coronal sections of E15.5 brains. Dashed lines mark the basal and apical margins of the VZ, SVZ, intermediate zone (IZ), and cortical plate (CP). Scale bar, 50 μm.(D) Histograms show the percentage of GFP+ cells in VZ, SVZ, IZ, and CP. ^∗∗^p \< 0.01 pCIG-*Bcl6*+pCIG versus pCIG and ^\#^p \< 0.05, ^\#\#\#^p \< 0.001 pCIG-*Bcl6*+pCAG-Δ(1-90)*Ctnnb1* versus pCIG-*Bcl6*+pCIG using two-way ANOVA followed by Tukey post hoc test.(E) Histograms show the percentage of Pax6+ and Tuj1+ cells among the GFP+ cells. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 pCIG-*Bcl6*+pCIG versus pCIG+pCIG and ^\#\#\#^p \< 0.001 pCIG-*Bcl6*+pCAG-Δ(1-90)*Ctnnb1* versus pCIG-*Bcl6*+pCIG using one-way ANOVA followed by Tukey post hoc test.Data are presented as mean + SEM of n = 6 control embryos (1,856 cells), n = 10 embryos for stabilized β-catenin gain of function (2,727 cells), n = 9 embryos for Bcl6 gain of function (1,922 cells), and n = 9 embryos for Bcl6 and stabilized β-catenin double gain of function (1,588 cells).(F--H) *In utero* electroporation of scramble (control), scramble+*Ctnnb1*, scramble+*Hes5*, scramble+*Ctnnb1*+*Hes5*, scramble+*Bcl6*, scramble+*Ctnnb1*+*Bcl6*, scramble+*Hes5*+*Bcl6*, and *Ctnnb1*+*Hes5*+*Bcl6* shRNAs at E13.5.(F) Representative images of Hoechst and GFP immunofluorescence performed on coronal sections of E16.5 brains. Dashed lines mark the basal and apical margins of the VZ, SVZ, IZ, and CP. Scale bar, 50 μm.(G) Histograms show the percentage of GFP+ cells in VZ, SVZ, IZ, and CP. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus control and ^\#^p \< 0.05, ^\#\#\#^p \< 0.001 versus *Bcl6*+control shRNAs using two-way ANOVA followed by Tukey post hoc test.(H) Histograms show the percentage of Pax6+ and β3-tubulin+ cells among the GFP+ cells. ^∗^p \< 0.05, ^∗∗^p \< 0.01 versus control and ^\#^p \< 0.05, ^\#\#^p \< 0.01, ^\#\#\#^p \< 0.001 versus *Bcl6*+control shRNAs using one-way ANOVA followed by Tukey post hoc test.Data are presented as mean + SEM of n = 15 control embryos (4,476 cells), n = 7 embryos for *Ctnnb1* shRNA (1,851 cells), n = 13 embryos for *Hes5* shRNA (3,893 cells), n = 7 embryos for *Ctnnb1*+*Hes5* shRNA (1,932 cells), n = 6 embryos for *Bcl6* shRNA (2,093 cells), n = 9 embryos for *Bcl6+Ctnnb1* shRNA (2,642 cells), n = 10 embryos for *Bcl6*+*Hes5* shRNA (2,614 cells), and n = 9 embryos for *Bcl6*+*Ctnnb1*+*Hes5* shRNA (2,993 cells).See also [Figures S2](#mmc1){ref-type="supplementary-material"}, [S3](#mmc1){ref-type="supplementary-material"}, and [S4](#mmc1){ref-type="supplementary-material"}.

On the other hand, these data suggest that Bcl6 neurogenic function could depend on the downregulation of the canonical Wnt pathway. We first tested this *in vitro* by examining potential genetic interactions between Bcl6 and β-catenin, the main signaling hub protein of the pathway. Neurogenic genes upregulated *in vitro* by Bcl6 were prevented by CHIR99021, a GSK3 inhibitor over-activating the canonical Wnt pathway. CHIR99021, which increased the levels of the Wnt reporter gene *Lef1*, also prevented Bcl6-mediated downregulation of Wnt target genes but did not prevent repression of Notch targets ([Figure S2](#mmc1){ref-type="supplementary-material"}K).

We then examined *in vivo* the impact of the gain of function of a stabilized β-catenin mutant on *Bcl6* overexpression using *in utero* electroporation. *Bcl6* gain of function alone led to increased neurogenesis, as assessed by increased number of cells in the cortical plate (CP) and an increase in Neurod2+ and Tuj1+ neurons, at the expense of ventricular zone (VZ)-located Pax6+ and Sox2+ progenitors, without detectable effect on neuronal migration or progenitor delamination ([Figures 2](#fig2){ref-type="fig"}C--2E and [S3](#mmc1){ref-type="supplementary-material"}A--S3G). Importantly, these effects were suppressed by overexpression of stabilized β-catenin ([Figures 2](#fig2){ref-type="fig"}C--2E and [S4](#mmc1){ref-type="supplementary-material"}C).

Conversely, we combined *Bcl6* and β-catenin (*Ctnnb1*) knockdown to assess potential epistasis. As expected ([@bib74]), *Bcl6* knockdown led to decreased neurogenesis per se, as reflected by increased cell number in the VZ at the expense of the CP, associated with increased levels of radial glial cell progenitors and decreased neurons ([Figures 2](#fig2){ref-type="fig"}F--2H and [S3](#mmc1){ref-type="supplementary-material"}H--S3N), and this phenotype was significantly rescued by the *Ctnnb1* knockdown ([Figures 2](#fig2){ref-type="fig"}F--2H).

These data collectively suggest that Bcl6 functionally acts on the Wnt pathway to promote neurogenesis, in addition to its effect on the Notch target *Hes5* ([@bib74]). We next directly compared the impact of Bcl6 on Wnt and Notch pathways *in vivo* by combining *Ctnnb1* and *Hes5* short hairpin RNAs (shRNAs) to further assess whether Bcl6 represses them in parallel or sequentially. *Hes5* knockdown rescued some of the *Bcl6* loss-of-function-mediated phenotype to levels similar to the rescue obtained using the *Ctnnb1* knockdown. However, the association of both *Ctnnb1* and *Hes5* shRNAs showed additive rescue of *Bcl6* knockdown, reaching the corresponding control levels (*Ctnnb1*+*Hes5* shRNA combination; [Figures 2](#fig2){ref-type="fig"}F--2H), suggesting that Bcl6 alters these two cascades at least in part in parallel.

Altogether, these data indicate that Bcl6-mediated repression of the Wnt pathway, already at the level of β-catenin, is necessary to elicit neurogenic activity, in parallel to Notch signaling repression. Thus, Bcl6 acts by repression of multiple pathways promoting progenitor self-renewal and proliferation.

As β-catenin is not only a key component of the Wnt pathway but also an important regulator of adherens junctions ([@bib60]), we tested further the specific implication of the Wnt pathway by focusing on *Tcf7l1*, which was also found to be downregulated in response to Bcl6 *in vitro* ([Figure S1](#mmc1){ref-type="supplementary-material"}A) and is the most heavily expressed Tcf/Lef transcription factor in cortical progenitors ([@bib16]).

Remarkably, we found that overexpression of *Tcf7l1* blocked Bcl6-mediated neurogenesis *in vivo* ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4D). Hence, these data strongly suggest that β-catenin downregulation by Bcl6 is mostly linked to its Wnt-related transcriptional activity rather than its activity in adherens junctions. This is in line with our RNA-seq analyses, which show that the expression of most genes related to adherens junctions tend to increase upon Bcl6 overexpression, especially *Jup*/γ-catenin ([Figure S1](#mmc1){ref-type="supplementary-material"}B), thereby compensating β-catenin decrease, as previously reported ([@bib80]).

Bcl6 Promotes Neurogenesis through Cyclin D Inhibition {#sec2.3}
------------------------------------------------------

Although Bcl6 appears to repress multiple serial components of individual pathways, it could also act through common effectors of parallel signals. In line with this hypothesis, *Cyclin d1/d2* genes were found to be downregulated by Bcl6 overexpression *in vitro* ([Figure 1](#fig1){ref-type="fig"}D; [Table S1](#mmc2){ref-type="supplementary-material"}) and are known to be upregulated by pathways driving progenitor self-renewal, including Wnt ([@bib71]) but also SHH ([@bib36], [@bib37]), FGF-insulin growth factor (IGF) ([@bib34], [@bib61]), and Notch ([@bib11]). Moreover, Cyclin d1/d2 are key promoters of cortical progenitor proliferation and consequently block neurogenesis ([@bib44], [@bib64], [@bib77]).

We first examined their expression in the developing cortex in wild-type and *Bcl6*^−/−^ brains. *Ccnd1* was found in the VZ and SVZ in wild-type mice as previously reported ([@bib20]), and its levels were significantly increased in *Bcl6*^*−/−*^ animals ([Figures 3](#fig3){ref-type="fig"}A and 3B). *Ccnd2* mRNA was mostly detected in basal endfeet of radial glial cells and at lower intensity in the ventricular zone at embryonic day 12.5 (E12.5), as previously described ([@bib77]). Although the high density of labeling and limited resolution of *in situ* hybridization precluded detecting upregulation in the basal endfeet, *Ccnd2* levels were significantly increased in the VZ in *Bcl6*^*−/−*^ cortex ([Figures 3](#fig3){ref-type="fig"}C and 3D). Hence, *Bcl6* negatively controls *Ccnd1/2* expression in cortical progenitors *in vivo*. We next examined the functional impact of *Bcl6* loss of function on *Ccnd1*/*Ccnd2* double knockdown, as these two cyclins regulate cell cycle progression in a redundant manner ([@bib9], [@bib20], [@bib77]). Decreased neurogenesis observed following *Bcl6* shRNA was completely rescued by the dual *Ccnd1*/*Ccnd2* knockdown ([Figures 3](#fig3){ref-type="fig"}E--3G and [S4](#mmc1){ref-type="supplementary-material"}E--S4G). Conversely, *Ccnd1* overexpression blocked Bcl6-elicited neurogenesis *in vivo* ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4D). This indicates that, in addition to repressing specific signaling pathway components, Bcl6 action also involves repression of common terminal effector targets, such as *Ccnd1/2*, driving progenitor proliferation and self-renewal.Figure 3*Bcl6* Directly Affects *Ccnd1*/*Ccnd2* Expression *In Vivo* to Promote Neurogenesis(A--D) *In situ* hybridization of (A) *Ccnd1* and (C) *Ccnd2* genes on coronal sections of E12.5 wild-type and *Bcl6*^−/−^ frontal and parietal telencephalon. Normalized gray scale quantifications of (B) *Ccnd1* and (D) *Ccnd2* levels were performed using ImageJ software. Data are presented as mean + SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01 using Student's t test. Black scale bars, 500 μm. Red scale bar, 100 μm.(E--G) *In utero* electroporation of scramble (control), scramble+*Ccnd1*+*Ccnd2*, scramble+*Bcl6*, and *Ccnd1*+*Ccnd2*+*Bcl6* shRNAs at E13.5.(E) Representative images of Hoechst and GFP immunofluorescence performed on coronal sections of E16.5 brains. Dashed lines mark the basal and apical margins of the VZ, SVZ, IZ, and CP. Scale bar, 50 μm.(F) Histograms show the percentage of GFP+ cells in VZ, SVZ, IZ, and CP. ^∗^p \< 0.01, ^∗∗^p \< 0.01 versus control and ^\#\#\#^p \< 0.001 versus *Bcl6*+control shRNAs using two-way ANOVA followed by Tukey post hoc test.(G) Histograms show the percentage of Pax6+ and β3-tubulin+ cells among the GFP+ cells. ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus control and ^\#\#\#^p \< 0.001 versus *Bcl6*+control shRNAs using one-way ANOVA followed by Tukey post hoc test.Data are presented as mean + SEM of n = 12 control embryos (3,627 cells), n = 7 embryos for *Ccnd1*+*Ccnd2* shRNA (1,519 cells), n = 8 embryos for *Bcl6* shRNA (1,998 cells), and n = 12 embryos for *Bcl6*+*Ccnd1*+*Ccnd2* shRNA (3,475 cells).See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}.

Bcl6 Represses Transcription through Sirt1-Mediated Histone Deacetylation as well as Target-Specific Mechanisms {#sec2.4}
---------------------------------------------------------------------------------------------------------------

Overall, our data indicate that Bcl6 acts through inhibition of multiple pathways to promote neurogenesis, raising the question of which effects are directly related to Bcl6 transcriptional repression or reflect its indirect consequences. To address this point, we performed chromatin immunoprecipitation (ChIP)-seq to identify Bcl6 binding sites using *in vitro* cortical progenitors driving inducible Bcl6 expression in order to increase the efficiency of the immunoprecipitation ([Figure S5](#mmc1){ref-type="supplementary-material"}). This revealed that Bcl6 binding was predominantly found on promoter regions, with a significant enrichment for Bcl6 matrix binding motif ([Figures S5](#mmc1){ref-type="supplementary-material"}A--S5D). Further, 39% of the Bcl6-predicted targets (1,701/4,366 peak-associated genes) were similar to those previously reported by ChIP-seq in human B cells ([@bib5]). In line with our transcriptomics data, Bcl6 bound to numerous genes of the multiple cascades regulating the proliferation of cortical progenitors ([Figure S5](#mmc1){ref-type="supplementary-material"}E), although it should be noted that only 19% of the downregulated genes from the RNA-seq dataset were found in the ChIP-seq screen (115/610 genes), indicating partial discrepancy between transcription factor binding and transcriptional effect, at least at the time points tested.

Then we validated *in vivo* some of these targets using ChIP-qPCR on the identified binding peaks in E12.5 wild-type and *Bcl6*^*−/−*^ cortex, focusing on Wnt and Notch pathways. We first confirmed Bcl6 binding to the Notch target *Hes5* but also identified additional Bcl6/Notch targets, such as *Hes1* and *Nrarp* ([Figures 4](#fig4){ref-type="fig"} and [S6](#mmc1){ref-type="supplementary-material"}A). Moreover, we found that Bcl6 bound to a repertoire of VZ-expressed genes of the Wnt/β-catenin cascade as well as potential Wnt/β-catenin targets, among which 10 showed significant downregulation upon Bcl6 induction in *in vitro* embryonic stem cell (ESC)-derived cortical progenitors, whether by RNA-seq or qRT-PCR, suggesting a direct functional impact following Bcl6 binding ([Figures 4](#fig4){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}D). The genes bound and regulated by Bcl6 ranged from Wnt receptors and co-receptors to intracellular effectors to Wnt target genes ([Figures 1](#fig1){ref-type="fig"}E, [4](#fig4){ref-type="fig"}B, and [S6](#mmc1){ref-type="supplementary-material"}E).Figure 4Bcl6 Binds to Core Genes of the Wnt/β-Catenin Pathway to Alter Their Expression(A) qRT-PCR analysis of Wnt-related genes from DMSO- and doxycycline-treated cells at day 12. Data are presented as mean + SEM of absolute levels (n = 21 from 8 differentiations). ^∗^p \< 0.05 and ^∗∗^p \< 0.01 using Student's t test.(B) ChIP-qPCR validation of screened Bcl6-binding sites on regulatory regions and negative control sites of significantly downregulated Wnt-related genes in E12.5 wild-type and *Bcl6*^−/−^ telencephalon using a Bcl6 antibody. Data are presented as mean + SEM of input enrichment (n = 4). ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 using Student's t test. Genes are represented using 5′ to 3′ orientation with light blue showing 5′ UTR and 3′ UTR exons and thicker dark blue showing the exons of the coding sequence and the introns according to RefSeq gene sequences from mouse genome mm10 assembly (<https://genome.ucsc.edu>). Black boxes indicate amplified regions (BS, region comprising the Bcl6-predicted binding site inside the ChIP-seq significant peaks; NEG, region with no predicted Bcl6 matrix using the Jaspar software \[<http://jaspar.genereg.net>\]).See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

We next examined how Bcl6 binding to its target sequences might lead to transcriptional repression. We previously found that Bcl6-mediated *Hes5* repression occurs through modifications of histone acetylation mediated by Sirt1 deacetylase recruitment ([@bib74]). Remarkably, we found a similar mechanism for all tested target genes identified above ([Figure 5](#fig5){ref-type="fig"}). Indeed, *in vivo* ChIP-qPCR experiments performed on mouse E12.5 embryonic cortex showed enrichment for acetylated lysines H4K16 and H1.4K26 on all tested genes in *Bcl6*^*−/−*^ cortex compared with wild-type, indicating that repressive chromatin remodeling required the presence of Bcl6 binding ([Figures 5](#fig5){ref-type="fig"}A and [S6](#mmc1){ref-type="supplementary-material"}B). Moreover, we detected binding of the histone deacetylase Sirt1 to all Bcl6-bound target genes, which was abolished in *Bcl6*^*−/−*^ cortex ([Figures 5](#fig5){ref-type="fig"}B and [S6](#mmc1){ref-type="supplementary-material"}C).Figure 5Bcl6 Binding to Significantly Downregulated Wnt-Related Genes Induces Chromatin Remodeling and Sirt1 Recruitment(A) ChIP-qPCR of histone acetylation marks on Bcl6 binding sites of significantly downregulated Wnt-related genes in E12.5 wild-type and *Bcl6*^−/−^ telencephalon using control (rabbit immunoglobulin G \[IgG\]) and H1.4K26ac and H4K16ac antibodies. Data are presented as mean + SEM of input enrichment (n = 6). ^∗^p \< 0.05 and ^∗∗^p \< 0.01 using Student's t test.(B) ChIP-qPCR on validated Bcl6 binding sites of significantly downregulated Wnt-related genes in E12.5 wild-type and *Bcl6*^−/−^ telencephalon using a Sirt1 antibody. Data are presented as mean + SEM of input enrichment (n = 6). ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 using Student's t test.See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

To test whether Sirt1 activity was indeed required for Bcl6 activity, we examined in more depth the transcriptional regulation of *Ccnd1/2.* Bcl6 was found to bind to their regulatory regions *in vitro*, together with Sirt1, in association with histone H4K16 deacetylation, as observed *in vivo* ([Figure 6](#fig6){ref-type="fig"}). Furthermore, we found that sirtuin activity inhibition effectively blocked the Bcl6-mediated *Ccnd1/2* downregulation, confirming the importance of Sirt1-dependent histone deacetylation in the repression of these genes by Bcl6 ([Figure S7](#mmc1){ref-type="supplementary-material"}A).Figure 6Bcl6 and Sirt1 Bind to *Ccnd1* and *Ccnd2* Regulatory Regions, Leading to the Removal of the β-Catenin Effector Tcf7l1(A) Schematic representation of the genomic region 2 kb upstream of *Ccnd1* and *Ccnd2* transcription starting sites showing validated Bcl6 (red) as well as putative Tcf7l1 (blue) binding sites and negative regions for either transcription factor (green) as predicted by the Jaspar software (<http://jaspar.genereg.net>). The arrows represent the amplified regions by qPCR used to measure the enrichment following ChIP.(B) ChIP-qPCR analysis of the Bcl6, Sirt1, and Tcf7l1 binding sites on the *Ccnd1* and *Ccnd2* regulatory regions in cortical progenitors derived from *Bcl6* A2 lox.Cre mouse ESCs (differentiation day 12, 24 h DMSO \[Ctrl\] or Dox treatment). Data are presented as mean + SEM of input enrichment (n = 3 differentiations). ^∗^p \< 0.05, ^∗∗^p \< 0.01, and ^∗∗∗^p \< 0.001 using Student's t test.(C) ChIP-qPCR analysis of the H4K16ac histone acetylation mark on Bcl6 binding sites of the *Ccnd1* and *Ccnd2* regulatory regions in cortical progenitors derived from *Bcl6* A2 lox.Cre mouse ESCs (differentiation day 12, 24 h DMSO \[Ctrl\] or Dox treatment). Data are presented as mean + SEM of input enrichment (n = 3 differentiations). ^∗^p \< 0.05 using Student's t test.See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

These data point to a generic mechanism by which a wide repertoire of the genes downregulated by Bcl6 and belonging to stem-cell-renewal signaling pathways are directly bound and repressed by Bcl6, which then recruits Sirt1, leading to their transcriptional silencing.

On the other hand, given the important role of Tcf7l1 in Bcl6 effects on neurogenesis, we examined in more detail the chromatin binding profiles of Tcf7l1 on the *Ccnd1/2* regulatory regions ([Figure 6](#fig6){ref-type="fig"}). This revealed that Tcf7l1 bound to both *Ccnd1/2* promoters on predicted Tcf/Lef binding sites, confirming their direct link with the Wnt pathway ([Figure 6](#fig6){ref-type="fig"}). Remarkably, this binding was decreased upon Bcl6 overexpression ([Figure 6](#fig6){ref-type="fig"}B). In contrast, Tcf7l1 binding at the level of the *Lef1* promoter, to which Bcl6 does not bind to, was unaffected ([Figures S7](#mmc1){ref-type="supplementary-material"}B and S7C). These data thus suggest that Bcl6 directly affects Tcf7l1 binding in a target-specific way, as an additional selective mechanism to modulate Wnt-dependent gene expression.

Discussion {#sec3}
==========

Neurogenesis is a key fate transition controlled by the interplay of intrinsic and extrinsic cues, but how these are integrated at the molecular level remains mostly unknown. Here, we identify the Bcl6 transcriptional repressor as a neurogenic factor that acts through the direct repression of a repertoire of genes encoding key components of numerous extrinsic morphogen pathways that promote self-renewal and proliferation of cortical progenitors, most strikingly the Wnt pathway. This provides important insight on the molecular logic by which neurogenic conversion can occur in a robust fashion in the presence of many, and sometimes contradictory, extrinsic cues.

Our transcriptome analysis shows that Bcl6 gain of function elicited a broad neurogenic program, from genes involved in the generation and expansion of intermediate progenitors to their differentiation into neurons, as well as neuronal maturation and specification, similarly to the response to the proneural *Neurog2* transcription factor in the developing cortex ([@bib21], [@bib32]). However, in the case of Bcl6, these effects are caused by a direct negative impact of Bcl6 on pathways promoting self-renewal and proliferation. Indeed, Bcl6 represses the transcription of genes related to most signaling cascades that favor the proliferation of cortical progenitors at the expense of their differentiation, most strikingly, the Notch and Wnt pathways, as well as SHH and FGF. Combining our RNA-seq results with ChIP experiments, we found that Bcl6 directly binds to most of these genes, leading to their transcriptional repression, even if future work will be needed to describe in depth Bcl6 direct repression on pathways other than Notch and Wnt.

This global effect is conceptually similar to the one previously proposed for Myt1l in the frame of neuronal reprogramming, where a single transcription factor appears to repress globally multiple non-neuronal fates to promote *in vitro* conversion into neurons ([@bib52]). It is also complementary to the classical effects of the Rest complex, which represses neuronal fate genes in non-neuronal cells ([@bib3]). In the case of Bcl6, however, the repression does not appear to act on fate-specific genes per se but rather on specific genes involved in extrinsic signaling pathways promoting progenitor maintenance. In this sense, Bcl6 acts probably mostly during fate transition itself, and this molecular logic could thereby explain how neuronal differentiation takes place irreversibly, even in the presence of proliferative extrinsic cues, thus providing robustness to the neurogenesis processes.

Interestingly, in the case of Wnt signaling, Bcl6 appears to act upon multiple components, from receptors to transducers and transcriptional effectors, as attested by the functional interactions between Bcl6 and β-catenin and Tcf7l1, as well as with Ccnd1/2, revealed in this study. This implies that, although Bcl6 can alter the intracellular response of Notch signaling in a target-specific way ([@bib68], [@bib74]), its effect on Wnt signaling appears to be much more global, from responsiveness to output. This may be related to the high complexity of the Wnt pathway, such as multiplicity of ligands and receptors and cell-dependent positive and negative feedback loops ([@bib10], [@bib51]), on which acting at multiple levels of repression may be required to achieve its robust silencing. Indeed, it should be noted that, although many of the Wnt components that are repressed are positive regulators of the pathway, some inhibitors of the pathway, such as *Sfrp1/2*, were also downregulated, and some activators, such as *Fzd8*, or inhibitors, such as *Dkk1*, were, most likely indirectly, upregulated. The same is true for the other examined morphogen pathways, thus suggesting that, although the overall effect of Bcl6 on these pathways is inhibitory, the net effect on some individual genes could sometimes result in transcriptional activation.

Moreover, the comparison of combined epistasis of *Bcl6* with *Hes5* and *Ctnnb1* revealed that Bcl6 appears to affect Notch and Wnt signaling in a parallel fashion rather than through a cascade of events following the alteration of a single upstream pathway. Furthermore, some Bcl6-elicited gene expression changes impact several pathways at the same time. For instance, we observed that Bcl6 gain of function decreases the expression of *Jag1* and *Nrarp*, which are both linked to Notch but also Wnt pathways ([@bib30], [@bib63]).

We identify *Ccnd1* and *Ccnd2* as major key targets of Bcl6, and their downregulation rescues to a large extent the loss of *Bcl6*. *Ccnd1* or *Ccnd2* were previously shown to act as key promoters of cortical progenitor proliferation and blockers of differentiation ([@bib44], [@bib64], [@bib77]) and are found downstream of most signaling pathways promoting progenitor self-renewal. This suggests a model whereby Bcl6 contributes to robustness of fate transition by also acting on key common downstream targets.

In principle, *Ccnd1/2* regulation by Bcl6 could contribute to other aspects of cortical development, such as area patterning ([@bib57]), given Bcl6 preferential expression in the frontal cortex and its effects on signaling cues, such as Wnts and FGFs that can also impact on cortical areal patterning ([@bib73], [@bib74]). However, our analyses of the cortex of *Bcl6* knockout mice failed to reveal any alteration in areal patterning, indicating that Bcl6 essential function is on the regulation of neurogenesis itself.

From a molecular viewpoint, Bcl6 appears to act through the same generic mechanism on most, if not all, of its targets, i.e., direct repression and Sirt1 recruitment, together with histone deacetylation that is correlated with decreased transcription. Interestingly, Bcl6 expression is progressively increased during the transition of radial glia cells into neurons either directly or indirectly though the generation of intermediate progenitors ([@bib74]), and Sirt1 expression appears to be constant in all cell types during cortical development ([@bib2], [@bib49]). Thus, the induction of Bcl6 expression and/or post-transcriptional mechanisms could precisely regulate the activity of the Bcl6-Sirt1 complex during the neurogenic transition; it will be interesting to identify whether this relies on extrinsic cues or intrinsic factors.

One striking effect of Bcl6 is direct repression of β-catenin, which is a key mediator of the Wnt pathway but also a critical regulator of adherens junctions, which are essential for proper function of radial glia progenitors ([@bib22]). It is therefore critical to disentangle the involvement of β-catenin either on cell adhesion or Wnt signaling ([@bib78]). In this frame, our data point to the conclusion that Bcl6-mediated repression of β-catenin to induce neurogenesis is mostly related to Wnt-dependent transcription and not on adherens junction regulation, which are likely to be maintained despite β-catenin downregulation through compensatory mechanisms, such as upregulation of γ-catenin ([@bib80]).

Moreover, in relation with β-catenin transcriptional activity, our data indicate that Tcf7l1 is a key mediator of Wnt signaling that is directly downstream of Bcl6. Wnt activation has been reported to have differential effects on neurogenesis ([@bib8], [@bib15], [@bib27], [@bib28], [@bib42], [@bib58], [@bib59], [@bib81], [@bib88]), and Tcf7l1 was previously proposed to act either as a repressor or an activator of transcription of Wnt-specific genes ([@bib12], [@bib39], [@bib50], [@bib72], [@bib82], [@bib84]). However, our data indicate that, in the context of Bcl6 effects on neurogenesis, Tcf7l1 acts mostly as a blocker of neurogenesis, in line with previous findings ([@bib62]), and thereby likely as an activator of pro-proliferative genes, such as *Ccnd1/2* identified in this study.

To sum up, our data identify a major role for Bcl6 during neurogenesis by the direct transcriptional repression of most signaling pathways promoting cortical progenitor self-renewal. As Bcl6 is expressed in only specific subsets of progenitors and neurons during brain development, future work should determine whether and how other transcriptional repressors in other parts of the nervous system can modulate responsiveness to extrinsic cues to ensure robust and irreversible neurogenic fate transition.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Genetically Modified Organisms**Bcl6tm2Rdf/Bcl6tm2Rdf mouse[@bib83]MGI Cat\# 3582783, RRID: MGI:3582783**Antibodies**Chicken anti-GFPAbcamCat\# ab13970, RRID: [AB_300798](nif-antibody:AB_300798){#intref0010}Rabbit anti-Pax6CovanceCat\# PRB-278P, RRID: [AB_291612](nif-antibody:AB_291612){#intref0015}Mouse anti-β3-tubulin (Tuj1)CovanceCat\# MMS-435P, RRID: [AB_2313773](nif-antibody:AB_2313773){#intref0020}Goat Sox2Santa Cruz BiotechnologyCat\# sc-17320, RRID: [AB_2286684](nif-antibody:AB_2286684){#intref0025}Mouse PCNAMilliporeCat\# MAB424, RRID: [AB_95106](nif-antibody:AB_95106){#intref0030}Rat Phospho-Histone H3AbcamCat\# ab10543, RRID: [AB_2295065](nif-antibody:AB_2295065){#intref0035}Rabbit Tbr2AbcamCat\# ab183991, RRID: [AB_2721040](nif-antibody:AB_2721040){#intref0040}Rabbit Neurod2AbcamCat\# ab104430, RRID: [AB_10975628](nif-antibody:AB_10975628){#intref0045}Alexa Fluor 488 anti-chickenThermo Fisher ScientificCat\# A-11039 RRID: [AB_2534096](nif-antibody:AB_2534096){#intref0050}Cyanine3 donkey anti-mouseJackson ImmunoResearchCat\# 715-165-150, RRID: [AB_2340813](nif-antibody:AB_2340813){#intref0055}Cyanine3 donkey anti-rabbitJackson ImmunoResearchCat\# 711-165-152, RRID: [AB_2307443](nif-antibody:AB_2307443){#intref0060}Rabbit IgG isotype controlAbcamCat\# ab171870, RRID: [AB_2687657](nif-antibody:AB_2687657){#intref0065}Rabbit anti-Bcl6Santa Cruz BiotechnologyCat\# sc-858, RRID: [AB_2063450](nif-antibody:AB_2063450){#intref0070}Rabbit anti-H1.4K26acSigma-AldrichCat\# H7789, RRID: [AB_1079058](nif-antibody:AB_1079058){#intref0075}Rabbit anti-H4K16acMilliporeCat\# 07-329, RRID: [AB_310525](nif-antibody:AB_310525){#intref0080}Rabbit anti-Sirt1MilliporeCat\# 07-131, RRID: [AB_10067921](nif-antibody:AB_10067921){#intref0085}Rabbit anti-Tcf7l1Prof. Brad MerrillN/A**Chemicals, Peptides, and Recombinant Proteins**CHIR 99021TocrisCat\# 4423CyclopamineCalbiochemCat\# 239803Doxycycline hydrochlorideSigma-AldrichCat\# D3447ESGRO Recombinant LIFMerckCat\# ESG1107N-2 SupplementThermo Fisher ScientificCat\# 17502048**Critical Commercial Assays**HiSeq PE Cluster Kit v4IlluminaCat\# PE-401-4001RNeasy mini kitQIAGENCat\# 74104TruSeq SBS Kit v3-HSIlluminaCat\# FC-401-3002TruSeq stranded mRNA library prepIlluminaCat\# RS-122-2101DIG RNA labeling kitRocheCat\# 11175025910**qPCR Primers**OligonucleotidesEurogentecSee [Table S4](#mmc5){ref-type="supplementary-material"}**Experimental Models: Cell Lines**A2 lox.Cre Bcl6 ES cells[@bib74]N/A**Experimental Models: Organisms/Strains**Mouse: ICR (CD1)Janvier labsStrain code 022**Deposited Data**ChIP-seqThis paperGEO: [GSE132964](ncbi-geo:GSE132964){#intref0090}RNA-seqThis paperGEO: [GSE133031](ncbi-geo:GSE133031){#intref0095}**Software and Algorithms**Bowtie[@bib45]<https://github.com/BenLangmead/bowtie>EdgeR 3.20.1[@bib66]<https://bioconductor.org/packages/release/bioc/html/edgeR.html>Fiji/ImageJ 1.49b[@bib70]<https://fiji.sc/>Genomic HyperBrowser[@bib69]<https://hyperbrowser.uio.no/hb/>GOrilla<http://cbl-gorilla.cs.technion.ac.il>GREAT 3.0[@bib56]<http://great.stanford.edu/public/html/>HTSeq 0.9.1[@bib1]<https://github.com/simon-anders/htseq>i-cisTarget[@bib29]<https://gbiomed.kuleuven.be/apps/lcb/i-cisTarget/>MACS[@bib87]<https://github.com/taoliu/MACS/>STAR 2.5.3a[@bib13]<https://github.com/alexdobin/STAR>UCSC Genome Browser[@bib38]<https://genome.ucsc.edu>ZEN Black microscope softwareZeissN/A**Other**Axioplan2 fluorescent microscopeZeissN/ALSM780 confocal microscopeZeissN/A

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for resources and reagents should be directed to, and will be fulfilled without restriction by, the Lead Contact Pierre Vanderhaeghen (<pierre.vanderhaeghen@kuleuven.vib.be>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Animals {#sec4.3.1}

All mouse experiments were performed with the approval of the Université Libre de Bruxelles Committee for animal welfare. Animals were housed under standard conditions (12 h light:12 h dark cycles) with food and water *ad libitum*. For in utero electroporation experiments, timed-pregnant mice were obtained by mating adult RjOrl:SWISS CD1 mice (Janvier, France). The plug date was defined as embryonic day E0.5. For experiments using *Bcl6*^*−/−*^ mice, we mated *Bcl6*^+/−^ mice (mixed C57BL/6 and CD1 background), in which the null allele lacked exons 4--10 ([@bib83]).

Method Details {#sec4.4}
--------------

### In Utero Electroporation {#sec4.4.1}

Timed-pregnant mice were anesthetized with a ketamine/xylazine mixture at E13.5. Each uterus was cautiously exposed under sterile conditions. Fast-green (Sigma)-labeled plasmid solutions were prepared using either 1 μg/μL or 0.5 μg/μL of appropriate DNA combinations for gain of function experiments or knockdown experiments, respectively. DNA solutions were injected into the lateral ventricles of the embryos using a heat-pulled glass capillary (1.0 OD x 0.78 × 100 L mm; Harvard Apparatus) prepared with a heat micropipette puller (heat: 580, pull: 100, velocity: 170, time: 120, pressure: 500; Sutter Instrument P-87). Electroporation was performed using tweezers electrodes (Nepa Gene CUY650P5) connected to a BTX830 electroporator (5 pulses of 30 V for 100 ms with an interval of 1 s). Embryos were placed back into the abdominal cavity, and mice were sutured and placed on a heating plate until recovery.

### Mouse ES cells and cortical differentiation {#sec4.4.2}

The A2 lox.Cre Bcl6 cell lines, tetracyclin-inducible Bcl6 ICE (A2lox.Cre) mouse Embryonic Stem Cells ([@bib74]), were routinely propagated on irradiated mouse embryonic fibroblasts in DMEM (Invitrogen) supplemented with 15% ESC-certified fetal bovine serum (vol/vol, Invitrogen), 0.1 mM non-essential amino acids (Invitrogen), 1 mM sodium pyruvate (Invitrogen), 0.1 mM β-mercaptoethanol (Sigma), 50 U.ml^−1^ penicillin/ streptomycin and 10^3^ U.ml^−1^ mouse Leukemia Inhibitor Factor (ESGRO). Results were obtained using three independent clones.

For differentiation, A2 lox.Cre Bcl6 mouse ESCs were plated at low density (20 × 10^3^ ml^−1^) on gelatin-coated coverslips and cultured as previously described ([@bib19]). Briefly, on day 0 of the differentiation, the ES medium was changed to DDM medium. At day 2, DDM was supplemented with cyclopamine (400 ng/mL, Calbiochem) and the medium was replenished every 2 days. After 10 days, medium was switched back to DDM. Doxycline treatment (1 μg.ml^−1^) for Bcl6 induction or DMSO (1:1000, control) was applied for 6,12 or 24 h at day 12. CHIR99021 (4 μM, Tocris) needed to be applied for 48h, i.e., from day 10, to effectively impact Wnt target genes.

### Plasmids {#sec4.4.3}

For *in situ* hybridization, the *Ccnd1* coding sequences (888 bp) and the *Ccnd2* 5′UTR+coding sequence (1145 bp) were amplified by PCR from ESC-derived cortical progenitor cDNA, and the sequences verified and cloned into pGEMT plasmid (Promega). The *Axin2* plasmid was a kind gift from Dr I. Garcia (ULB) and the *Lmo4* plasmid was a kind gift from Prof. J.L.R. Rubenstein (UCSF), who received it from Prof. G.N. Gill (UCSD). For in utero electroporations, the *Bcl6* coding sequence was amplified by PCR from cDNA and cloned into p*CAG*-IRES-*GFP* (pCIG). The p*CAG*-Δ90*Ctnnb1* plasmid (N-terminal deletion lacking GSK3-dependent S^33^, S^37^ and T^41^ phosphorylation sites) was obtained from Addgene (plasmid \#26645). The p*CAG-Ccnd1* and p*EF1α-Tcf7l1* plasmids were kind gifts from Dr C. Dehay and Prof. R. Kageyama, respectively. The shRNA plasmids were cloned downstream of the *U6* promoter into the pSilencer2.1-CAG-Venus (pSCV2)-plasmid as previously described ([@bib74]) with the exception of the *Ctnnb1* shRNA plasmid (pLKO.1-puro vector, Sigma). Target sequences were 5′-ACTACCGTTGTTATAGGTG-3′ (Control; [@bib74]), 5′-TGATGTTCTTCTCAACCTTAA-3′ (*Bcl6*; [@bib74], [@bib86]), 5′-CCCAAGCCTTAGTAAACATAA-3′ (*Ctnnb1*; [@bib53]), 5′- AGCCTGCACCAGGACTAC-3′ (*Hes5*; ([@bib46]), 5′-CCACAGATGTGAAGTTCATTT-3′ (*Ccnd1*; [@bib31], [@bib85]), 5′-CGACTTCAAGTTTGCCATGTA-3′ (*Ccnd2*; [@bib17]) and were previously validated in the corresponding references.

### Immunofluorescence {#sec4.4.4}

Embryos were fixed by transcardiac perfusion with freshly-prepared 4% paraformaldehyde (Sigma). Brains were dissected, and 100 mm sections were prepared using a Leica VT1000S vibrosector. Slices were transferred into PBS with 0.5 μg/mL sodium azide (Sigma), then blocked with PBS supplemented with 3% horse serum (Invitrogen) and 0.3% Triton X-100 (Sigma) during 1 h, and incubated overnight at 4°C with the following primary antibodies: chicken GFP (Abcam, 1:2,000), rabbit Pax6 (Covance, 1:1000), Sox2 (Santa Cruz Biotechnology, 1:500), PCNA (Millipore, 1:200), phospho-Histone H3 (Abcam, 1:100), Tbr2 (Abcam, 1:500), Neurod2 (Abcam, 1:500), or mouse β3-tubulin (Tuj1 epitope, Covance, 1:1000). After three washes with PBS/0.1% Triton X-100, slices were incubated in PBS for 1 h at room temperature and incubated 2 h at room temperature with the appropriated Alexa 488 (1:1,000, Molecular Probes), Cyanine 3 or Cyanine 5 (1:400, Jackson ImmunoResearch) secondary antibodies. Sections were again washed three times with PBS/0.1% Triton X-100, stained with Hoechst (bisBenzimide H 33258, Sigma) for 5 min and washed twice in PBS. The sections were next mounted on a Superfrost slide (Thermo Scientific) and dried using a brush before adding Glycergel mounting medium (Dako). Imaging was performed using a Zeiss LSM780 confocal microscope controlled by the Zen Black software (Zeiss).

### Transcriptome analyses {#sec4.4.5}

Total mRNA from four independent samples from ESc-derived cortical differentiations (day 12 ± doxycycline) was extracted using the QIAGEN RNeasy mini kit according to the manufacturer's recommendations. Following RNA quality control assessed on a Bioanalyzer 2100 (Agilent technologies), the indexed cDNA libraries were prepared using the TruSeq stranded mRNA Library Preparation kit (Illumina) following manufacturer's recommendations. The multiplexed libraries (18 pM) were loaded on flow cells and sequences were produced using a HiSeq PE Cluster Kit v4 and TruSeq SBS Kit v3-HS from a Hiseq 1500 (Illumina). Approximately 20 million of paired-end reads per sample were mapped against the mouse reference genome (GRCm38.p4/mm10) using STAR 2.5.3a software ([@bib13]) to generate read alignments for each sample. Annotations Mus_musculus.GRCm38.87.gtf were obtained from [ftp.Ensembl.org](http://ftp.Ensembl.org){#intref0160}. After transcript assembling, gene level counts were obtained using HTSeq 0.9.1 ([@bib1]). EdgeR 3.20.1 ([@bib66]) was then used to calculate the level of differential gene expression. Gene Ontology analyses of biological processes were performed using the GOrilla application (<http://cbl-gorilla.cs.technion.ac.il>).

### RT-qPCR {#sec4.4.6}

Reverse transcription of mature mRNAs was done with the Superscript II kit (Invitrogen) using the manufacturer's protocol for oligo dTs. Quantitative PCR (qPCR) was performed in duplicate using Power Sybr Green Mix (Applied Biosystems) and a 7500 Real-Time PCR System (Applied Biosystems). Results are presented as linearized Ct values normalized to the housekeeping gene *Tbp* (2^−ΔCt^) and the primers are listed in the [Table S4](#mmc5){ref-type="supplementary-material"}.

### *In situ* RNA hybridization {#sec4.4.7}

Whole-mount *in situ* hybridization as well as on coronal and sagittal cryosections was performed using digoxigenin-labeled RNA probes (DIG RNA labeling kit, Roche) and alkaline phosphatase revelation (NBT/BCIP kit \#SK-5400; Vector) as previously described ([@bib43]). The above-mentioned plasmids were linearized and reverse-transcribed to generate the anti-sense probes. Sense probes were used as a negative control for each gene tested and revealed no specific staining (data not shown). Images were acquired with a Zeiss Axioplan 2 microscope and a Spot RT3 camera using the Spot 5.2 software. For quantifications, littermate embryos were compared using 3 animals/genotype from 3 different litters for *Axin2* and *Ccnd2* or 6 embryos/genotype from 4 different litters (*Ccnd1*). Quantifications of gray densities were done on comparable levels of the dorsal primordium of the frontal cortex using ImageJ software ([@bib70]).

### Chromatin Immunoprecipitation {#sec4.4.8}

A2 lox.Cre Bcl6 cells and E12.5 *Bcl6* WT and KO telencephalons were fixed with 1% formaldehyde in phosphate-buffered saline and then lysed, sonicated, and immunoprecipitated as described previously ([@bib6]). Immunoprecipitations were performed using IgG isotype control (ab171870, Abcam), Bcl6 (sc-858, Santa Cruz Biotechnology), H1.4K26ac (H7789, Sigma-Aldrich), H4K16ac (07-329, Millipore), Sirt1 (07-131, Millipore), and Tcf7l1 (kind gift from Prof. Brad Merrill) rabbit antibodies and 50/50 mixed protein A and protein G magnetic Dynabeads (ThermoFisher Scientific). Primers used for ChIP-qPCR were designed to surround the predicted Bcl6 matrices present in the significant peaks of the ChIP-seq screen and are listed in the [Table S4](#mmc5){ref-type="supplementary-material"}.

### ChIP-seq {#sec4.4.9}

Following chromatin immunoprecipitation using A2 lox.Cre Bcl6 cells (differentiation day 12, 24h Bcl6 induction using 1 μg.ml^−1^ Doxycline treatment) as described above, ChIP libraries were prepared according to the standard Illumina ChIP-seq protocol and were sequenced with the Genome Analyzer IIx (Illumina) as previously described ([@bib55]). Reads from three independent ChIP-seq experiments were pooled and aligned to mm10 mouse genome assembly using Bowtie ([@bib45]). Peaks were then called using MACS ([@bib87]) with standard parameters with default cutoff p value \< 10e-5. Target genes associated with peaks were identified by GREAT version 3.0 ([@bib56]). ChIP-seq dataset for the Bcl6-predicted target genes were visualized using the UCSC Genome Browser ([@bib38]). Search for an enrichment of Bcl6 matrices in the MACS-called ChIP peaks was performed using i-cisTarget ([@bib29]) using a promoter-only database.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Results are shown as mean ^±^ standard error (SEM) of at least three biologically independent experiments. Student's unpaired t test was used for two group comparisons. Analyses of multiple groups were performed by a one-way or two-way analysis of variance (ANOVA) - as indicated in figure legends - followed by post hoc multiple comparisons using Tukey's test. Hypothesis testing for overlap analysis was performed using the Genomic HyperBrowser (<https://hyperbrowser.uio.no/hb/>; [@bib69]). For all tests, a p value inferior to 0.05 was taken as statistically significant.

Data and Code Availability {#sec4.6}
--------------------------

RNA-seq raw data are shown on [Table S5](#mmc6){ref-type="supplementary-material"} and the complete dataset is available at GEO repository (GEO: [GSE133031](ncbi-geo:GSE133031){#intref0175}). The ChIP-seq dataset is available at GEO repository (GEO: [GSE132964](ncbi-geo:GSE132964){#intref0180}).
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Document S1. Figures S1--S7Table S1. RNA-Seq Analysis upon Bcl6 Induction in *In Vitro* Cortical Progenitors, Related to Figure 1RNA-seq dataset of the significantly up- and downregulated genes following Bcl6 expression in cortical progenitors derived from A2 lox.Cre cells (differentiation day 12, 24 h DMSO (control) or doxycycline treatment).Table S2. Gene Ontology Analyses of the Ranked Up- and Downregulated Genes from the RNA-Seq Dataset, Related to Figure 1BGO analysis was performed using the GOrilla software (<http://cbl-gorilla.cs.technion.ac.il>).Table S3. Complete Gene Set Used for the Analysis of Transcriptional Changes Elicited by Bcl6 Overexpression on Wnt, Notch, SHH, and FGF-Insulin-IGF Proliferative Pathways in *In Vitro* Cortical Progenitors, Related to Figure 1DSignificantly up- and downregulated genes are shown in red and blue, respectively. Genes marked with an asterisk are target genes of the pathway itself. Potential target genes highlighted in green show expression in cortical progenitors according to literature data when available or online data sets (<http://developingmouse.brain-map.org>, <http://www.genepaint.org>, <https://medicine.yale.edu/lab/rakic/transcriptome/>).Table S4. Oligonucleotide Sequence for qRT-PCR and ChIP-qPCR, Related to STAR MethodsTable S5. RNA-Seq Raw Data Counts, Related to STAR MethodsDocument S2. Article plus Supplemental Information
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